Serum Institute of India becomes the first indigenous company to seek COVID vaccine approvals.

After Pfizer, the Serum Institute of India (SII) has also sought permission for Emergency Use of CoviShield. With this, the Serum Institute has become the first indigenous company in India, which is ready to launch the Corona vaccine in the market. The news agency quoted sources as saying that Serum has applied for this to the Drugs Controller General of India (DCGI) on Sunday. So far 96.73 lakh people have been infected in India.

According to the Indian Institute of Medical Research (ICMR), the Serum Institute has produced 40 million doses of Coveshield of Oxford and AstraZeneca. Serum stated in its application that vaccines in the UK (two clinical tests), Brazil and India (one test each) have been found to have good affixi (90%) to fight the disease. From the safety point of view, no adverse effect was revealed in the trial of KoviShield. Hence the vaccine can be given to a targeted population.

Serum is the world’s largest vaccine manufacturer. The company has handed over 12 batches of vaccine for testing to Central Drugs Laboratory (CDL) based in Kasauli.

On December 4, American company Pfizer sought approval from the Indian drug controller for emergency use of its vaccine. The UK and Bahrain have approved the introduction of Pfizer’s vaccine. India has already made it clear that any vaccine will be brought in the country only when it completes clinical trials here. According to media reports, Pfizer or its associate company denied any such trial. However, officials say DCGI can waive local clinical trials if desired.